AstraZeneca submits NDA

AZN submitted an NDA to the FDA for a fast-dissolving formulation of its Zomig zolmitriptan oral 5HT1D receptor agonist to treat migraine. The formulation, which is marketed in Europe, uses OraSolv dr...